In contrast, we found a consistent statistically significant elevated risk associated with EPT use both at baseline and in the sub-cohort with FUQ data for BC overall, invasive and in situ disease, and for histologic and hormone receptor subtypes, with significant dose-response effects across doses and EPT regimens. This evidence concerns the gene NR4A1 and breast cancer.